The efficiency of non-specific inhaled immunotherapy with ruzam in patients with atopic bronchialasthma

Background. To study the efficacy and safety of inhaled form of ruzam in adult patients with persistent mildand moderate atopic bronchial asthma (ba).Materials and methods. a placebo-controlled prospective, randomized, open label study of an efficacy of ruzama solution for inhalations (in bottles on 2,5 or 5 ml) on 2,5 ml onсe a day through nebulizer during 2 weeks wasconducted in adult asthmatic patients. The efficacy of therapy was evaluated by dynamics of symptoms and requirementin ƒ2-agonists, besides PEfr, spirometry, bronchial hyperresponsiveness (bhr), asthma control test(aCT ), level of the markers of the allergic inflammation were performed.Results. reduction of bа symptoms, increase morning PEfr, decrease of bhr and NОex level in patients whoreceived ruzam compared with control group was observed. achievement of clinical control of bа in patientstreated by ruzam was accompanied by statistically significant positive dynamics of markers of inflammation(ifNg, ECP) in blood serum and in supernatant of the induced sputum. it testifies about anti-inflammatory influenceof ruzam.Conclusion. inhaled therapy with ruzam in a complex with iNCs basic therapy is an effective and safe methodof treatment of persistent atopic bronchial asthma. This combination allows to reach clinical and functionalcontrol of ba faster and to reduce inflammation markers in blood serum and induced sputum.